KR20220044720A - 환자를 계층화하기 위한 분류기의 개발 - Google Patents

환자를 계층화하기 위한 분류기의 개발 Download PDF

Info

Publication number
KR20220044720A
KR20220044720A KR1020227002006A KR20227002006A KR20220044720A KR 20220044720 A KR20220044720 A KR 20220044720A KR 1020227002006 A KR1020227002006 A KR 1020227002006A KR 20227002006 A KR20227002006 A KR 20227002006A KR 20220044720 A KR20220044720 A KR 20220044720A
Authority
KR
South Korea
Prior art keywords
subject
therapy
disease
responsive
classifier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227002006A
Other languages
English (en)
Korean (ko)
Inventor
수잔 기아시안
디오도르 알. 멜로스
마크 산토리니
애셔 아멜리
낸시 쉔브루너
비아체슬라브 알. 아크매브
케이스 제이. 존슨
Original Assignee
사이퍼 메디슨 코퍼레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사이퍼 메디슨 코퍼레이션 filed Critical 사이퍼 메디슨 코퍼레이션
Publication of KR20220044720A publication Critical patent/KR20220044720A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Primary Health Care (AREA)
  • Data Mining & Analysis (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Databases & Information Systems (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
KR1020227002006A 2019-06-27 2020-06-26 환자를 계층화하기 위한 분류기의 개발 Pending KR20220044720A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962867853P 2019-06-27 2019-06-27
US62/867,853 2019-06-27
US201962882402P 2019-08-02 2019-08-02
US62/882,402 2019-08-02
US202062965486P 2020-01-24 2020-01-24
US62/965,486 2020-01-24
PCT/US2020/039991 WO2020264426A1 (en) 2019-06-27 2020-06-26 Developing classifiers for stratifying patients

Publications (1)

Publication Number Publication Date
KR20220044720A true KR20220044720A (ko) 2022-04-11

Family

ID=74061318

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227002006A Pending KR20220044720A (ko) 2019-06-27 2020-06-26 환자를 계층화하기 위한 분류기의 개발

Country Status (11)

Country Link
US (5) US11195595B2 (https=)
EP (1) EP3990656B1 (https=)
JP (1) JP2022541125A (https=)
KR (1) KR20220044720A (https=)
CN (1) CN114402084A (https=)
AU (1) AU2020308906A1 (https=)
CA (1) CA3145237A1 (https=)
GB (1) GB2603294A (https=)
IL (1) IL289304A (https=)
MX (1) MX2022000128A (https=)
WO (1) WO2020264426A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7496324B2 (ja) 2018-03-16 2024-06-06 サイファー メディシン コーポレイション 抗ｔｎｆ療法に対する応答性を予測するための方法及びシステム
GB2603294A (en) 2019-06-27 2022-08-03 Scipher Medicine Corp Developing classifiers for stratifying patients
WO2021231713A2 (en) 2020-05-14 2021-11-18 Ampel Biosolutions, Llc Methods and systems for machine learning analysis of single nucleotide polymorphisms in lupus
KR20240018404A (ko) * 2020-09-01 2024-02-13 사이퍼 메디슨 코퍼레이션 항-tnf 요법에 대한 반응을 예측하기 위한 방법 및 시스템
US11430575B2 (en) * 2020-11-13 2022-08-30 Specialty Diagnostic (SDI) Laboratories, Inc. Systems and methods for a data driven disease test result prediction
US12271832B2 (en) * 2021-02-12 2025-04-08 Tempus Ai, Inc. Artificial intelligence engine for directed hypothesis generation and ranking
AU2022240733A1 (en) * 2021-03-19 2023-09-28 Scipher Medicine Corporation Methods of classifying and treating patients
WO2022240875A1 (en) 2021-05-13 2022-11-17 Scipher Medicine Corporation Assessing responsiveness to therapy
US20220399092A1 (en) * 2021-06-10 2022-12-15 Rajant Health Inc. Ai-enabled health platform
JP2024527529A (ja) * 2021-06-22 2024-07-25 サイファー メディシン コーポレーション 治療モニタリングおよび試験設計のための方法とシステム
WO2023150731A2 (en) * 2022-02-04 2023-08-10 Scipher Medicine Corporation Systems and methods for predicting response to anti-tnf therapies
CN114861764B (zh) * 2022-04-11 2024-11-22 中国科学院计算技术研究所 基于auc优化的多类别分类方法及系统
CN115206439B (zh) * 2022-05-20 2025-07-18 南开大学 跨语言平台的空间转录组数据转换方法及系统
WO2024081737A1 (en) * 2022-10-12 2024-04-18 Exagen Inc. Biomarker selection for machine learning enabled prediction of treatment response
CN116312796B (zh) * 2022-12-27 2023-11-14 江苏先声医学诊断有限公司 一种基于期望最大化算法的宏基因组丰度估计方法及系统
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040120952A1 (en) 2000-08-07 2004-06-24 Centocor, Inc Anti-TNF antibodies and peptides of human tumor necrosis factor
EP1945814A2 (en) 2005-09-27 2008-07-23 Source MDX Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis
CN103336129A (zh) 2005-11-01 2013-10-02 阿布维生物技术有限公司 使用生物标志物诊断强直性脊柱炎的方法和组合物
WO2007123976A2 (en) * 2006-04-18 2007-11-01 The Board Of Trustees Of The Leland Stanford Junior University Antibody profiling for determination of patient responsiveness
WO2008150491A2 (en) 2007-05-31 2008-12-11 Abbott Laboratories BIOMARKERS PREDICTIVE OF THE RESPONSIVENESS TO TNFα INHIBITORS IN AUTOIMMUNE DISORDERS
US20100303813A1 (en) 2007-06-08 2010-12-02 Biogen Idec Ma Inc. Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
US7863021B2 (en) 2007-09-05 2011-01-04 Celera Corporation Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof
WO2009102957A2 (en) 2008-02-14 2009-08-20 The Johns Hopkins University Methods to connect gene set expression profiles to drug sensitivity
EP2307563B1 (en) 2008-03-28 2014-08-06 Katholieke Universiteit Leuven KU Leuven Research & Development Mucosal gene signatures
KR20100003759A (ko) 2008-07-02 2010-01-12 양혜지 반짝이가 포함된 구두약
ES2445892T3 (es) 2008-08-25 2014-03-05 Janssen Biotech, Inc. Biomarcadores para el tratamiento anti-TNF en colitis ulcerosa y trastornos relacionados
EP2342664A1 (en) 2008-09-03 2011-07-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Computer implemented model of biological networks
CA2737485A1 (en) 2008-10-10 2010-04-15 Mount Sinai Hospital Methods for classifying samples based on network modularity
JP5996429B2 (ja) 2009-09-03 2016-09-21 ジェネンテック， インコーポレイテッド 関節リウマチの治療、診断及びモニターするための方法
WO2011047358A1 (en) 2009-10-15 2011-04-21 Crescendo Bioscience Biomarkers and methods for measuring and monitoring inflammatory disease activity
WO2011139345A2 (en) 2010-04-29 2011-11-10 The Regents Of The University Of California Pathway recognition algorithm using data integration on genomic models (paradigm)
US10192641B2 (en) 2010-04-29 2019-01-29 The Regents Of The University Of California Method of generating a dynamic pathway map
WO2012066536A2 (en) 2010-11-16 2012-05-24 Prediguard Transcriptome signatures discriminate etanercept-treated rheumatoid arthritis (ra) patients according to their response or refractory status
EP2668287B1 (en) 2011-01-25 2017-09-06 TC LAND Expression Genes and genes combinations based on gene mknk1 predictive of early response or non response of subjects suffering from rheumatoid arthritis to tnf-alpha blocking monoclonal antibody
US20130040835A1 (en) 2011-05-05 2013-02-14 Exagen Diagnostics, Inc Genes predictive of anti-TNF response in inflammatory diseases
AU2012253422B2 (en) 2011-05-10 2015-08-13 Société des Produits Nestlé S.A. Methods of disease activity profiling for personalized therapy management
CN104955845B (zh) 2012-09-27 2018-11-16 美国政府(由卫生和人类服务部的部长所代表) 间皮素抗体和引起有效的抗肿瘤活性的方法
HU230680B1 (hu) 2012-10-19 2017-08-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Diagnosztikai eljárás
EP2914739B1 (en) 2012-11-05 2017-09-13 Novigenix SA Biomarker combinations for colorectal tumors
WO2014082083A1 (en) 2012-11-26 2014-05-30 Caris Science, Inc. Biomarker compositions and methods
US10161936B2 (en) 2013-03-08 2018-12-25 University Of Leipzig Method and kit for cytokine analysis from a human whole blood sample
US9945870B2 (en) 2013-05-17 2018-04-17 The Board Of Trustees Of The Leland Stanford Junior University Methods for determining responsiveness to an anti-CD47 agent
WO2015006213A1 (en) 2013-07-08 2015-01-15 Northeastern University Methods for identifying complex disease subtypes
US9387246B2 (en) 2013-09-03 2016-07-12 L. Douglas Graham Treatment methods for rheumatoid arthritis
WO2015084461A2 (en) 2013-09-23 2015-06-11 Northeastern University System and methods for disease module detection
WO2015148809A1 (en) 2014-03-27 2015-10-01 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
WO2015153437A1 (en) 2014-04-02 2015-10-08 Crescendo Bioscience Biomarkers and methods for measuring and monitoring juvenile idiopathic arthritis activity
WO2015164406A1 (en) 2014-04-21 2015-10-29 University Of South Florida Salivary inflammatory biomarkers associated with glycemic control and oral health
CA2964857A1 (en) 2014-10-20 2016-04-28 Nestec S.A. Methods for prediction of anti-tnf alpha drug levels and autoantibody formation
HK1244881A1 (zh) 2014-12-02 2018-08-17 Société des Produits Nestlé S.A. 建立维多珠单坑给药方案以治疗患有易激惹肠病的患者的方法
EP3730188B1 (en) * 2015-08-21 2024-07-31 The Children's Hospital of Philadelphia Compositions and methods for use in combination for the treatment and diagnosis of autoimmune diseases
ES2905536T3 (es) * 2015-10-02 2022-04-11 Momenta Pharmaceuticals Inc Procedimientos terapéuticos y de diagnóstico para enfermedades autoinmunes y/o inflamación
US10018637B2 (en) 2015-10-06 2018-07-10 Celgene International Ii Sarl Methods for treating inflammatory and other diseases and the use of biomarkers as predictors of clinical sensitivity to treatment with apremilast
ES2716900T3 (es) 2015-11-06 2019-06-17 Promise Advanced Proteomics Un método para cuantificar anticuerpos anti-TNF
US20190080051A1 (en) 2015-11-11 2019-03-14 Northeastern University Methods And Systems For Profiling Personalized Biomarker Expression Perturbations
US20170145501A1 (en) 2015-11-20 2017-05-25 Lasse Folkersen Apparatus and methods of using of biomarkers for predicting tnf-inhibitor response
EP3440579A4 (en) 2015-11-24 2020-03-25 Klaritos, Inc. INNOVATIVE MODEL OF DELIVERY, PROCESSING AND PAYMENT FOR SPECIALIZED MEDICINES
GB201521357D0 (en) 2015-12-03 2016-01-20 Univ Liverpool Methods for predicting response to anti-TNF therapy
JP6572120B2 (ja) 2015-12-14 2019-09-04 浜松ホトニクス株式会社 光ビーム照射装置
WO2017151755A1 (en) 2016-03-02 2017-09-08 Crescendo Bioscience Biomarkers and methods for predicting response to discontinuation of inflammatory disease therapy
AU2017281039A1 (en) 2016-06-20 2019-01-24 Healthtell Inc. Methods for differential diagnosis of autoimmune diseases
US12105089B2 (en) 2017-07-17 2024-10-01 The Broad Institute, Inc. Cell atlas of the healthy and ulcerative colitis human colon
US20200165677A1 (en) 2017-07-18 2020-05-28 Thaddeus Stappenbeck Methods and uses of inflammatory bowel disease biomarkers
US10512775B2 (en) * 2017-08-30 2019-12-24 Cochlear Limited Noise reduction for implantable hearing prostheses
US20190287644A1 (en) 2018-02-15 2019-09-19 Northeastern University Correlation Method To Identify Relevant Genes For Personalized Treatment Of Complex Disease
JP7496324B2 (ja) 2018-03-16 2024-06-06 サイファー メディシン コーポレイション 抗ｔｎｆ療法に対する応答性を予測するための方法及びシステム
EA202191354A1 (ru) 2018-11-15 2021-08-11 Янссен Байотек, Инк. Способы и композиции для прогнозирования ответа на терапию воспалительного заболевания кишечника
AU2020244763A1 (en) 2019-03-22 2021-09-30 Inflammatix, Inc. Systems and methods for deriving and optimizing classifiers from multiple datasets
JP7621967B2 (ja) 2019-03-28 2025-01-27 フェーズ ゲノミクス インコーポレイテッド シーケンシングによる核型分析のためのシステムおよび方法
GB2603294A (en) 2019-06-27 2022-08-03 Scipher Medicine Corp Developing classifiers for stratifying patients
KR20240018404A (ko) 2020-09-01 2024-02-13 사이퍼 메디슨 코퍼레이션 항-tnf 요법에 대한 반응을 예측하기 위한 방법 및 시스템
AU2022240733A1 (en) 2021-03-19 2023-09-28 Scipher Medicine Corporation Methods of classifying and treating patients
WO2023150731A2 (en) 2022-02-04 2023-08-10 Scipher Medicine Corporation Systems and methods for predicting response to anti-tnf therapies

Also Published As

Publication number Publication date
JP2022541125A (ja) 2022-09-22
US12062415B2 (en) 2024-08-13
US12525318B2 (en) 2026-01-13
AU2020308906A1 (en) 2022-02-03
US20210280271A1 (en) 2021-09-09
WO2020264426A1 (en) 2020-12-30
US11195595B2 (en) 2021-12-07
US20230386606A1 (en) 2023-11-30
MX2022000128A (es) 2022-04-27
CN114402084A (zh) 2022-04-26
IL289304A (en) 2022-02-01
EP3990656A1 (en) 2022-05-04
US20220101946A1 (en) 2022-03-31
US11456056B2 (en) 2022-09-27
CA3145237A1 (en) 2020-12-30
GB202119148D0 (en) 2022-02-16
EP3990656A4 (en) 2023-12-06
GB2603294A (en) 2022-08-03
US20240355416A1 (en) 2024-10-24
EP3990656B1 (en) 2026-04-22
US11783913B2 (en) 2023-10-10
US20220375541A1 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
US12525318B2 (en) Method of monitoring anti-TNF therapy in a subject suffering from rheumatoid arthritis based in part on a trained machine learning classifier
US20240199729A1 (en) Methods and systems for predicting response to anti-tnf therapies
WO2022271724A1 (en) Methods and systems for therapy monitoring and trial design
US20230282367A1 (en) Methods and systems for predicting response to anti-tnf therapies
US20250270307A1 (en) Methods of classifying and treating patients
KR20240044417A (ko) 개인맞춤형 요법을 위한 방법 및 시스템
CN117916392A (zh) 用于疗法监测和试验设计的方法和系统
EP4247980A2 (en) Determination of cytotoxic gene signature and associated systems and methods for response prediction and treatment
CA3212448A1 (en) Methods of classifying and treating patients
CN117813402A (zh) 分类和治疗患者的方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000